Key statistics
As of last trade Chemomab Therapeutics Ltd (2QV0:FRA) traded at 1.46, -27.72% below its 52-week high of 2.02, set on Sep 06, 2024.
52-week range
Open | 1.50 |
---|---|
High | 1.50 |
Low | 1.46 |
Bid | 1.46 |
Offer | 1.60 |
Previous close | 1.50 |
Average volume | 169.00 |
---|---|
Shares outstanding | 18.51m |
Free float | 14.64m |
P/E (TTM) | -- |
Market cap | 29.61m USD |
EPS (TTM) | -0.9868 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
Announcements
- Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
- Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
- Chemomab Therapeutics to Present at October 2024 Investor Conferences
- Chemomab Therapeutics to Present at September 2024 Investor Conferences
- Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Therapeutics Announces Closing of $10 Million Private Placement
- Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
More ▼